No. PDRN stands for polydeoxyribonucleotide, a fragment of DNA — a chain of nucleotides. A peptide is a chain of amino acids. These are two different classes of molecule, and no definition of peptide includes DNA. The brand itself is straightforward about this and describes the ingredient as a DNA component derived from salmon; it is the product category name, sold as a peptide serum, that invites the confusion. The product does also contain five genuine peptides, listed separately.

Why does the ingredient list not say PDRN?

Because supplier and marketing terms are not permitted in a US ingredient declaration; 21 CFR 701.3(c) requires the established name. The established name here is Sodium DNA, and that is what sits at position five on the label. The word PDRN appears on the front of the package and nowhere in the list. A shopper checking the declaration for the ingredient the product is named after will not find it unless they already know the translation.

Which peptides are actually in it?

Five, at consecutive positions seven to eleven: copper tripeptide-1, which is the INCI name for GHK-Cu; acetyl hexapeptide-8, sold as Argireline; palmitoyl pentapeptide-4, the peptide in Matrixyl; palmitoyl tripeptide-1; and palmitoyl tetrapeptide-7. Each has its own published evidence file, and we have written all five up separately. Grouping them consecutively on the label is normal for a peptide complex added as a single premix.

How much PDRN is in the serum?

The brand states 10,000 parts per million of salmon PDRN, which is 1.0 percent. That figure is consistent with where the ingredient appears: 21 CFR 701.3(f)(2) allows ingredients at or below 1 percent to be listed in any order, and Sodium DNA sits at position five with everything from position six onward in the unordered tail. For once the label and the marketing number agree with each other, which is worth noting because they frequently do not.

What does the research on PDRN actually cover?

Mostly injection, and mostly not cosmetics. A PubMed search on 2026-09-16 found 219 records with polydeoxyribonucleotide in the title and just 2 randomized controlled trials involving skin — a 2025 acne-scar study combining PDRN injections with botulinum neurotoxin, and a 2001 pilot in skin-explant patients. Neither tested a topical product. The wider topical set is 25 records and includes oral mucositis, ocular wound healing and genital lichen sclerosus, none of which is a cosmetic serum on intact facial skin.

Is there any study of PDRN applied topically to normal skin?

Nothing that answers the question for a serum. The nearest is a 2022 paper in Molecules that tested a liquid of PDRN with vitamin C and niacinamide in UV-B irradiated animals — and delivered it through a microneedling therapy system, which breaches the barrier the topical question is about. Three actives together in an animal model through a device is a legitimate experiment, and it cannot tell anyone what a mixture spread on intact human skin does. That gap is the central fact about this ingredient's cosmetic use.

Has Peptide Glow Journal tested this serum?

No. Nothing here comes from using the product. We assess a product only after six weeks of split-face use by two testers, photographed to a fixed standard, and that has not happened. This page reads the published ingredient declaration against the published literature on the ingredients in it, and says where that literature stops.

Medicube PDRN Pink Peptide Serum: PDRN Is Not a Peptide, and It Is Not on the Label

The molecule in the product name is a DNA fragment, not a peptide, and the declaration calls it Sodium DNA. The five actual peptides sit at positions seven to eleven — and PDRN's clinical literature is an injection literature.

This product is named after an ingredient that is not a peptide and does not appear on its own ingredient list under the name on the box. Both of those facts are checkable in about two minutes, and between them they explain most of what is confusing about the category this serum leads.

What the declaration actually says

Forty ingredients are declared. The first eleven:

Position	Ingredient
1	Water
2	Disodium EDTA
3	Niacinamide
4	Hydrolyzed Collagen
5	Sodium DNA ← this is the PDRN
6	Millet Extract
7	Copper Tripeptide-1
8	Acetyl Hexapeptide-8
9	Palmitoyl Pentapeptide-4
10	Palmitoyl Tripeptide-1
11	Palmitoyl Tetrapeptide-7

Search the full list for "PDRN" and you get nothing. Search it for "polydeoxyribonucleotide" and you get nothing. The ingredient is there — it is Sodium DNA, the INCI name for the sodium salt of deoxyribonucleic acid — but the word the product is sold under is not a permitted label name. Under 21 CFR 701.3(c), ingredients must be declared by their established names, and marketing terms are not established names. We set out how often this gap bites in our guide to reading a peptide ingredient list.

PDRN is a nucleic acid, not a peptide

PDRN is polydeoxyribonucleotide: a chain of nucleotides, extracted in this case from salmon DNA. A peptide is a chain of amino acids. These are not neighbouring categories with a fuzzy border; they are two different polymer classes built from two different monomer types, doing two different things in a cell.

The brand is not concealing this. Its own copy calls the ingredient a DNA component similar to human DNA and names salmon as the source. The confusion is structural rather than deceptive: the product is called a peptide serum, PDRN is the headline of the name, and a reader who assumes the headline ingredient is the peptide has made a reasonable inference from a package that does not correct it.

The peptides are real and they are separate — five of them, at positions seven to eleven. Every one has an evidence file here already: copper tripeptide-1, which is GHK-Cu, acetyl hexapeptide-8, sold as Argireline, palmitoyl pentapeptide-4, the Matrixyl peptide, palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.

The one percent that checks out

The brand states 10,000 ppm of salmon PDRN. That is 1.0 percent — the arithmetic is direct, since parts per million divided by ten thousand gives percent.

It is worth doing because the figure lands exactly on the regulatory line. 21 CFR 701.3(f)(2) lets ingredients present at not more than 1 percent be listed without respect to order of predominance. Sodium DNA sits at position five; the peptides sit at six through eleven, in the tail where order stops being required to carry information. The published percentage and the published list are consistent with each other, which is not always the case and is worth saying when it is.

What follows from it is the ordinary constraint: the five peptides are each at 1 percent or less, individually unquantified, exactly as on every other peptide product. Our peptide serum page works through why that ceiling is all a label can give you.

Where the PDRN research actually lives

This is the part that changes how the ingredient should be read, and it is a counting exercise anyone can repeat.

PubMed search, run 2026-09-16	Records
polydeoxyribonucleotide in the title	219
…and skin in the title or abstract	45
…randomized controlled trials involving skin	2
polydeoxyribonucleotide with topical or cosmetic	25

Two hundred and nineteen papers is a real literature. The question is what it is a literature about.

Both randomized skin trials administered PDRN by injection. One is a 2025 Aesthetic Plastic Surgery study of botulinum neurotoxin and polydeoxyribonucleotide injections for acne scars — a combination, injected. The other is a 2001 Current Medical Research and Opinion pilot on the trophic effect of PDRN in patients undergoing skin explants. Neither is a test of a serum.

The twenty-five topical-or-cosmetic records are a mixed set: radiation-induced oral mucositis, corneal epithelial healing in mice, genital lichen sclerosus, post-cauterisation cervical therapy from 1989 and 1990, and a cluster of recent laboratory papers on plant- and algae-derived polydeoxyribonucleotides in cell culture.

The closest thing to the product's own use case is a 2022 paper in Molecules testing a topical liquid of PDRN, vitamin C and niacinamide. Three things about it matter, and all three are in the abstract: it was run in UV-B irradiated animals, not humans; it tested the three actives as a mixture, so nothing in the result can be assigned to PDRN; and it was delivered through a microneedling therapy system, which perforates the barrier that the topical question exists to ask about. Our page on microneedling and copper peptides has the measured version of why that distinction is decisive — 134 nmol of peptide crossed microneedled human skin in nine hours against almost none through intact skin.

So the honest summary of the evidence position: PDRN has a substantial clinical literature built on injecting it, and an essentially absent one on spreading it on undamaged skin. A serum is the second thing.

What this formula establishes

It establishes an ingredient list that is accurate and a product name that is not descriptive. It establishes five peptides, each at 1 percent or less, each with its own separately documented evidence. It establishes 1 percent of a salmon-derived DNA fragment whose research record is about a different route of administration.

It does not establish what the serum does on a face, and this page makes no claim about that. We have not used it. What a formula can tell you is what is in the bottle and what has been published about those things — and here, the most useful sentence available is the simplest one: the molecule on the front of the package is not a peptide.

Sources

Medicube PDRN Pink Peptide Serum, published ingredient declaration — ingredient listing, read 2026-09-16; brand claims and the 10,000 ppm figure as published by the brand and its retailers, read 2026-09-16.
21 CFR 701.3, Designation of ingredients — eCFR, paragraphs (c) and (f)(2), read 2026-09-16.
PubMed counts via NCBI E-utilities, run 2026-09-16; records identified: PMID 40826297 (acne-scar injection trial, 2025) and PMID 11759182 (skin-explant pilot, 2001).
Kim HM, Byun K-A, et al. A Mixture of Topical Forms of Polydeoxyribonucleotide, Vitamin C, and Niacinamide Attenuated Skin Pigmentation and Increased Skin Elasticity by Modulating Nuclear Factor Erythroid 2-like 2. Molecules 2022;27(4):1276 — PubMed 35209068.